Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Conditions: Breast Neoplasms Interventions: Drug: Disitamab Vedotin; Drug: Toripalimab Sponsors: RemeGen Co., Ltd. Not yet recruiting

Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials